SCHEMBL3326110

SCHEMBL3326110

NS(=O)(=O)c1ccc(C(=O)OCCCN2CCCCC2)cc1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.70
HRH3 Q9Y5N1 8/20 0.66
KCNH2 Q12809 5/20 0.66
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
CA12 O43570 3/20 0.56
CA1 P00915 3/20 0.56
CA2 P00918 3/20 0.56
CA9 Q16790 3/20 0.56
CA4 P22748 1/20 0.56
CA7 P43166 2/20 0.51
CA14 Q9ULX7 2/20 0.51
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327501 0.99 CYP2D6 (0.67) CYP2D6HRH3KCNH2MEN1KMT2A
SCHEMBL3325835 0.92 KMT2A (0.68) CYP2D6HRH3KCNH2MEN1KMT2A
SCHEMBL3322597 0.91 KMT2A (0.66) CYP2D6HRH3KCNH2MEN1KMT2A
SCHEMBL14178114 0.85 CA12 (0.52) CYP2D6HRH3KCNH2CA12CA1
SCHEMBL11638745 0.84 CYP2D6 (0.77) CYP2D6HRH3KCNH2MEN1KMT2A
SCHEMBL14178128 0.82 HRH3 (0.48) CYP2D6HRH3KCNH2MEN1KMT2A
SCHEMBL8355590 0.81 CYP2D6 (0.76) CYP2D6HRH3KCNH2MEN1KMT2A
Hydrochloric Acid SCHEMBL8622970 0.80 CYP2D6 (0.74) CYP2D6HRH3KCNH2MEN1KMT2A
SCHEMBL14178096 0.79 KCNH2 (0.47) CYP2D6HRH3KCNH2MEN1KMT2A
SCHEMBL26814865 0.78 CYP2D6 (0.71) CYP2D6HRH3KCNH2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142499-B1 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma UNIMED PHARMA SPOL SRO (SK) 2014-12-10 EP claimed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US claimed
US-8193184-B2 Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use Unimed Pharma, SPOL, S.R.O. (SK) 2012-06-05 US disclosed
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE UNIMED PHARMA, SPOL. S R.O. (SK) 2010-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125076-A1 SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE ARSA, SMS, SULT1E1 CYP2D6 174/4885HRH3 20/4885KCNH2 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.